Clinical Efficacy of Osimertinib Combined with Gemcitabine in the Treatment of Elderly Pa-tients with Advanced NSCLC and Renal Metastasis
[Objective]To investigate the clinical efficacy and survival status of osimertinib combined with gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer(NSCLC)and renal metastasis.[Methods]A total of 238 elderly patients with advanced NSCLC admitted to our hospital were ran-domly divided into the control group and the observation group,with 119 cases in each group.The control group was treated with osimertinib,while the observation group was additionally treated with cisplatin and gemcitabine.The efficacy after 3 treatment cycles,changes in tumor markers and renal function indicators be-fore and after treatment,drug safety,and 1-year survival status were compared between the two groups.[Re-sults]The clinical control rate in the observation group was higher than that in the control group(P＜0.05).After treatment,the levels of carcinoembryonic antigen(CEA),pro-gastrin-releasing peptide(ProGRP),and squamous cell carcinoma antigen(SCCA)were lower in both groups compared to before treatment(P＜0.05),with the observation group showing even lower levels than the control group(P＜0.05).There were no significant differences in blood urea nitrogen and serum creatinine levels between the two groups before and after treatment(P＞0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).The 1-year overall survival curve of the observation group was better than that of the control group(P＜0.05).[Conclusion]The treatment regimen of osimertinib combined with gemcitabine for elderly patients with advanced NSCLC and renal metastasis is significantly effective,which can reduce tumor markers,provide short-term survival benefits,and has good safety.
万方数据
维普
